United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Acquires 42,308 Shares of Zoetis Inc. $ZTS

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund grew its holdings in Zoetis Inc. (NYSE:ZTS) by 19.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 263,349 shares of the company’s stock after acquiring an additional 42,308 shares during the quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Zoetis were worth $33,135,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ZTS. Vanguard Group Inc. boosted its position in shares of Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares during the period. Diamond Hill Capital Management Inc. bought a new stake in shares of Zoetis in the third quarter valued at approximately $394,010,000. Nordea Investment Management AB boosted its position in shares of Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares during the period. Montrusco Bolton Investments Inc. boosted its position in shares of Zoetis by 256.7% in the fourth quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock valued at $266,888,000 after acquiring an additional 1,560,314 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Zoetis by 83.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock valued at $394,746,000 after acquiring an additional 1,227,085 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 1.4%

Shares of ZTS stock opened at $78.36 on Friday. The stock has a market cap of $32.85 billion, a P/E ratio of 12.99, a price-to-earnings-growth ratio of 1.30 and a beta of 0.87. Zoetis Inc. has a one year low of $72.38 and a one year high of $172.23. The stock has a fifty day moving average price of $105.08 and a 200 day moving average price of $117.31. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may help reassure investors by giving management a venue to discuss strategy, operations, and the path forward. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
• Neutral Sentiment: Argus reiterated a “hold” rating on Zoetis, suggesting analysts are not currently seeing a major catalyst for a near-term rebound. Zoetis had its “hold” rating reaffirmed by Argus
• Negative Sentiment: Multiple law firms announced or expanded class action efforts against Zoetis, with investors alleging harm tied to the period from January 14, 2025 through May 6, 2026; these repeated filings keep legal overhang front and center for shareholders. Rosen Law Firm Urges Zoetis Inc. (NYSE: ZTS) Stockholders to Contact the Firm for Information About Their Rights
• Negative Sentiment: The lawsuits stem from Zoetis’ Q1 results, when the company missed earnings and revenue estimates and cut full-year guidance, raising concerns about growth and execution. Zoetis (ZTS) Securities Fraud Investigation – Levi & Korsinsky

Insider Buying and Selling

In related news, Director Paul Bisaro acquired 2,000 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 11,650 shares of company stock valued at $886,384 over the last ninety days. 0.22% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday. UBS Group reduced their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research report on Friday, May 15th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $133.92.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.